Skip to main contentSkip to navigationSkip to search

ICE 2026

CAM2029 maintains IGF-I and acromegaly symptom control across the 4-week dosing interval and intervals >28 days: data from ACROINNOVA 1

Click the material you wish to view

ACROINNOVA 1-IGF-1-stability

Pdf 0.5 MB

ACROINNOVA 1-IGF-1-stability Suppl

ZIP 1.2 MB

See all posters presented at
ICE 2026

Explore more

Disease areas

Camurus is committed to improving treatment outcomes and quality of life for people with severe and chronic diseases.

Congresses

Discover Camurus’ engagement at conducted and upcoming international medical conferences and events.